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Abstract: Although the chemical warfare between invasive and native species has become a central
problem in invasion biology, the molecular mechanisms by which bioactive metabolites from invasive
pests influence local communities remain poorly characterized. This study demonstrates that the
alkaloid caulerpin (CAU)—a bioactive component of the green alga Caulerpa cylindracea that has
invaded the entire Mediterranean basin—is an agonist of peroxisome proliferator-activated receptors
(PPARs). Our interdisciplinary study started with the in silico prediction of the ligand-protein
interaction, which was then validated by in vivo, ex vivo and in vitro assays. On the basis of
these results, we candidate CAU as a causal factor of the metabolic and behavioural disorders
observed in Diplodus sargus, a native edible fish of high ecological and commercial relevance,
feeding on C. cylindracea. Moreover, given the considerable interest in PPAR activators for the
treatment of relevant human diseases, our findings are also discussed in terms of a possible
nutraceutical/pharmacological valorisation of the invasive algal biomasses, supporting an innovative
strategy for conserving biodiversity as an alternative to unrealistic campaigns for the eradication of
invasive pests.
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1. Introduction
Biological invasions are a main component of global change with profound ecological, economic
and social consequences [1]. They are also of great concern for marine ecosystems [2], particularly for
the Mediterranean Sea, where dense carpets of invasive algae are transforming vast coastal areas into
alarming monocultures. Furthermore, recent research has emphasized the urgency of investigating
metabolites produced by invasive plants and animals as stress factors in marine environments [3–5].
Since the pioneering efforts of Ernesto Fattorusso [6,7], both marine macrophytes and dinoflagellates
are especially known to contain several bioactive natural products of ecological and ecotoxicological
interest [8,9]. In this respect, crucial questions have been raised by some of the worst invasive
macroalgae in the Mediterranean Sea, belonging to the genus Caulerpa [4,5,10–12]. Among them,
C. cylindracea (previously known as C. racemosa var. cylindracea), which is native to South-western
Australia [8], has become widely diffused in the whole Mediterranean, with profound consequences
for native species resulting in significant ecological and economical costs. Currently, this invasive
alga represents an important food item for the white sea bream Diplodus sargus (family: Sparidae),
which is both a keystone species playing a major role in controlling the abundance of sea urchins in
the Mediterranean [13–15], and a commercial species largely appreciated for human nutrition [11].
The novel diet of white sea bream (see supplementary Video S1 showing a juvenile specimen
of D. sargus swallowing the invasive alga with evident voracity) is attracting the increasing interest
of researchers and local media since it correlates with metabolic disorders in the fish and with a
decrease of essential lipids in its flesh [11,12,16–18]. The altered lipid metabolism of the fish could be
explained by a combination of factors, including low levels of essential fatty acids in C. cylindracea
and the possible role of algal metabolites as regulators of lipid metabolism in fish [11,12]. It is
noteworthy that crude C. racemosa extracts turned out to also have dyslipidaemic effects in rats [19].
However, the molecular interactions between bioactive metabolites from Caulerpa species and their
macromolecular targets responsible for the observed effects have remained unclear. In D. sargus, it has
been shown that a Caulerpa-based diet alters the activity/expression of several proteins involved in
lipid metabolism, including peroxisome proliferator-activated receptor alpha (PPARα), whose gene
transcription was enhanced [12]. Moreover, there is an intriguing connection with other studies
showing a decrease in both palatability and nutritional values in edible fish exposed to environmental
concentrations of fenofibrate (FFB), a PPARα agonist with a recognized ecotoxicological potential.
FFB, commonly used as a lipid-lowering drug in humans, induces lipid metabolism abnormalities
and decreases EPA and DHA content when administered to freshwater fish (rainbow trout and grass
carp) [20,21]. It is worthy to note that the same effect has been observed in wild populations of D. sargus
feeding on C. cylindracea [11]. This observation is consistent with the PPARα-mediated transcription
of genes related to hepatic β-oxidation, such as carnitine palmitoyltransferase 1 (CPT1) [22].
Remarkably, the algal secondary metabolite caulerpin (CAU, Figure 1a), which accumulates in
the tissues of D. sargus and other edible Mediterranean fish species [11,12,16–18,23], shows several
functional similarities to FFB since both compounds: (i) suppress activation of hypoxia-inducible
factor-1 (HIF-1) [24,25], (ii) inhibit protein tyrosine phophatase-1B (PTP1B) [26,27] and (iii) show
anti-inflammatory properties [28,29]. In addition, the PPARα-mediated effects of FFB on the social
interaction of mice [30] can be paralleled to the ability of CAU of influencing the social behaviour in
D. sargus [31]. However, despite considerable past efforts to identify the molecular targets of CAU,
its possible direct interactions with PPARα, the main target of FFB, has not yet been investigated.
The same applies to the possible interaction of CAU with the PPARγ isoform, which is also expressed
in brain areas involved in regulation of behavioural processes in vertebrates [32,33]. We thus tested
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here if CAU, although exhibiting a totally different molecular scaffold from classical PPAR ligands,
could modulate PPARα/γ transcriptional activity by direct ligand binding. This hypothesis was first
addressed by in silico studies to predict the possible interaction of CAU with both the α and γ PPAR
isoforms and then validated by luciferase reporter assays. Furthermore, the functional similarities
between CAU and FFB have been deeply investigated by in vivo, ex vivo and in vitro experiments
coupled with transcriptional analysis of genes of the PPARα signalling pathway.
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Figure 1. Structural comparison between CAU a lective PARα agonist. (a) CAU 2D structure
and (b) a 3D fit of CAU (thick sti s, carbon = cyan) o GW590735 (thin sticks, carbon = green), a potent
and selective PPARα agonist, showing the “V-shaped” structure shared by the two molecules.
2. Results
2.1. Computational Stud es
By applying a ligand-based approach, we found that the rigid and V shaped bis-indolic structure
of CAU (Figure 1a) shows a good overall fit with the bioactive conformations of classical PPARs
ligands, an example of which is shown in Figure 1b; however, none of the CAU carboxymethyl-groups
overlaps the carboxylic functional group occurring in the reference ligands.
These contrasting features definitively called for a target-based approach to check if the overall
scaffold, including the orientation of its functional groups, was compatible with a PPARα and/or
PPARγ agonist activity. Since such an approach needed a three-dimensional structure for PPAR targets
and currently only partial PPARs sequences from fish of the family Sparidae are available, we decided
to compare these sequences to the human ones, for which high-resolution reference structures are
available. Results are shown in Figure 2.
As an example, a multi-alignment between two sparid fish (Sparus aurata and Dentex dentex) and
human PPARα sequences (Figure 2) shows that both sparids share 68% of sequence identity and 80%
of positives with the human protein in the Ligand Binding Domain (LBD) and that all the critical
residues for agonist interaction are conserved among the species, the only relevant insertion being
located in the flexible Ω-loop.
Molecular docking studies followed by molecular dynamics (MD) simulations were thus
undertaken for CAU on the crystallographic structures of both hPPARα and hPPARγ LBD,
encompassing helices H3, H4-5, H7, H11, H12 and the β-sheet. The six representative poses, selected
as described in the methods section, are shown in Figure 3. Three poses in PPARα (I–III, panels a,b)
and two in PPARγ (I, II, panels a,b) embr ce helix H3, while the ligand in PPARγ III pose runs almost
parallel to helix H3 (pa l c). On pose in both receptors (PPARα/γ IV, panel d) is located between
helix H3 and β-sheet, one (PPARα/γ V, panel e) is oriented toward β-sheet and one (PPARα/γ VI,
panel f), located between helices H3 and H7, embraces helix H5. In all the selected poses of both
isoforms, CAU forms mainly hydrophobic ligand-protein interactions, enforced in some poses by
H-bonds. In particular, for PPARα, CAU H-bonds with an occurrence >10% over MD production runs
are detected with S280/T279 (pose II), I354CObb/T279 (III), Y334NHbb (IV) and S280/T279 (VI), where
“bb” subscripts indicate protein backbone groups. In PPARγ complexes, CAU features intermolecular
H-bonds with S342/R288 (V) and S289 (VI). The LDB region spanned by CAU poses overlaps with
that of other PPARγ partial agonists in crystallographic structures, for example, magnolol [34], where
two different orientations of the ligand occur in the LBD.
Mar. Drugs 2018, 16, 431 4 of 16
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Figure 3. Representative MD structures of PPAR-CAU complexes. Panels a-f show CAU and
representative MD structures of PPARα-CAU (magenta) and PPARγ-CAU (gold) complexes. In
particular, panels show PPARα/γ I (a), PPARα II, III (this latter in mauve)/PPARγ II (b), PPARγ III
(c), PPARα/γ IV (d), PPARα/γ V (e) and PPARα/γ VI (f) complex structures from MD representative
frames. Proteins and ligands are shown as half-transparent pipes-and-planks and opaque stick with
non-carbon atoms coloured by type (red: oxygen, blue: nitrogen, white: hydrogen), respectively.
Complexes are grouped by similarity and shown in the same orientation, resulting from a recursive
best-fit of protein heavy atoms, iterated by pruning distant atom pairs until no pair exceeds 2.0 Å.
Mar. Drugs 2018, 16, 431 5 of 16
2.2. Luciferase Reporter Assays
The predicted dual PPARα/γ partial agonist behaviour of CAU was then validated by PPARα
and PPARγ luciferase reporter assays on COS-7 cells, in comparison with FFB and rosiglitazone (RGZ),
chosen as PPARα and PPARγ selective agonists, respectively (Figure 4a,b). The results show the
activation of PPARα- and PPARγ-mediated transcription after exposure to CAU 10 µM and 30 µM,
with levels comparable to those induced by FFB 10 µM and RGZ 0.01 µM. In addition, since luciferase
assays were based on the co-expression of PPAR/RXR heterodimers, we also used the RXRα/Gal4
system to rule out the direct activation of RXR (Figure 4c) by CAU. The obtained results clearly
supported a dual PPARα/γ partial agonist behaviour of CAU.
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2.3. In Vivo Studies on D. sargus
The report d functio al similarities betwe n CAU and FFB led us to perform further investigations
on the PPARα i oform, which the main molecular target of FFB. In particular, manipulative
experiment allowed us to test the hypothesis that oral administration of purified CAU can influence
PPARα gene expression in D. sargus.
Juvenile fish were fed in controlled aquarium conditions for one month with CAU-enriched
food. Subsequently, accumulation of CAU was evaluated in fish tissues (Figure 5a), showing that
liver, brain and, to a lower extent, white muscle were able to accumulate orally-administered CAU.
The measurement of relatively high levels of CAU in D. sargus brain provides the first evidence, to our
knowledge, that the compound can cross the fish blood-brain bar ier (BBB). Strikingly, accumulation
of CAU in fish l ver wa paralleled by a significant upregulation f PPARα (Figu e 5b), with nduction
levels comparable to those previously measured for D. sargus under field conditions [12].Mar. Drugs 2018, 16, x FOR PEER REVIEW  6 of 16 
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2.4. Ex Vivo Studies on Precision-Cut Liver Slices (PCLS) of D. sargus and In Vitro Exposures of HepG2 Cells
Experiments with PCLS of D. sargus confirmed similar trend in PPARα target gene induction by
CAU and FFB (Figure 6a–c).
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Figure 6. Ex vivo and in vitro experiments. (a–c) Time-dependent R levels of PPARα, ACADM
and ACOX1 under exposure of precision-cut tissue slices of D. sargus liver to either CAU or FFB
(n = 3 for each bar). (d–g) Time-dependent expression of PPARα responsive genes in HepG2 cells.
qPCR analyses were performed comparing PPARα (d), ACADM (e), ACOX1 (f) and CPT1A (g) gene
expression relative to DMSO in cells treated with CAU and FFB at 6 h (n = 4), 24 h (n = 3) and 48 h
(n = 4). (h) Expression of CPT1A protein in HepG2 cells (western blot) at 48 h (n = 2). Averaged optical
density (OD) values for the CPT1A bands were normalized to that of α-tubulin. (i) MTT assays on
HepG2 cells (n = 3). Statistical analyses were performed using unpaired t-tests. * p < 0.05 vs. vehicle
(DMSO). Error bars indicate standard error of the mean.
In particular, mRNA levels of ACADM increased after 12 h exposure to both CAU (3.4-fold)
and FFB (1.9-fold) and ACOX1 showed a high up-regulation after 24 h exposure (3.0 and 3.6-fold
for CAU and FFB, respectively). When assayed in a dose-dependent manner in a simpler cellular
model (HepG2 cells), CAU and FFB induced the expression of PPARα responsive genes functioning
in mitochondrial (ACADM, CPT1A) and peroxisomal (ACOX1) fatty acid β-oxidation (Figure 6d–g).
In addition, we found significant overexpression of carnitine palmitoyltransferase 1A (CPT1A) protein
at 48 h following CAU treatment in the same model (Figure 6h). The MTT viability assay demonstrated
no cytotoxicity after exposure to CAU (Figure 6i).
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3. Discussion
Although the increasing worldwide challenges raised by invasive species have attracted the
attention of both biologists and global change researchers, it is still unclear what evolutionary responses
should be expected in native species exposed to bioactive molecules never encountered before.
The activity and selectivity of bioactive compounds regulating fundamental processes such as
development, reproduction, defense and nutrition, which sensibly affect ecosystem structure and
stability, is mostly the result of long-term evolutionary trends. Conversely, compounds from invasive
pests may start exerting unexpected and dramatic effects on the native communities, also playing a
critical role in the behaviour, spread and impact of the invaders [4], thus significantly contributing to
the rapid evolutionary changes characterizing biological invasions.
In the present study, we focused on D. sargus, a fish with a fundamental ecological role in the
Mediterranean, being the most important species involved in the sea-urchin cascade [14,15]. This fish
also has substantial social and economic importance, representing a fishing target for direct human
nutrition. Our previous investigations on this species revealed the onset of oxidative stress conditions
related to the dietary accumulation of CAU, an alkaloid abundant in the green alga C. cylindracea, which
is highly invasive in the Mediterranean and has become an important food item in the diet of D. sargus.
In particular, the dietary exposure to C. cylindracea was shown to alter fatty acids metabolism and
gene expression in D. sargus [12,23], acting as a relevant biotic stressor. However, the algal metabolites
directly involved in the fish metabolic disorders were still unknown.
In this report we candidate the interaction of CAU with PPARs, which are nuclear receptor proteins
that function as transcription factors for genes involved in cellular differentiation, development,
inflammation and lipid metabolism, as a possible cause of alterations in fish lipid metabolism.
In particular, we hypothesize and provide evidence for the direct binding and the activation by
CAU of PPARα and PPARγ.
The functional analogies between CAU and the PPARα agonist FFB [24–29] led us to focus on
the target genes of this PPAR isoform involved in fatty acid metabolism in tissues with high oxidative
rates such as muscle, heart and liver. Some of such target genes, indeed, were upregulated by CAU in
both the ex vivo and the in vitro model, supporting a role of CAU in the activation of lipid β-oxidation
pathways. This explains, at least in part, the cellular and physiological alterations observed in fish
eating C. cylindracea, which lead to a detrimental health status and altered behaviour, potentially
preventing the reproductive success of fish populations [23].
Cascade effects of such molecular interactions still remain to be elucidated on the entire
Mediterranean ecosystem, in which D. sargus is one of the main controllers of the abundance of
major benthic grazers [35]. Nonetheless a PPARα mediated fat loss in D. sargus and other edible marine
fish, similar to that induced by FFB on freshwater fish [20,21], would most likely produce a severe
economic impact to the fishery sector. National newspapers have already reported a significant change
in the organoleptic properties of D. sargus flesh as a possible consequence of the novel diet of based on
C. cylindracea [36,37]. In addition, the interaction of CAU with PPARα and PPARγ, both expressed in
brain areas involved in regulation of behavioural and emotional processes in rodents [30,32,33], could
also result in PPAR-mediated altered social behaviour of D. sargus. Indeed, dietary CAU is already
known to reduce the aggressive behaviour of D. sargus [31]. Since small molecules must cross the BBB
to have an effect on centrally-mediated behaviours, the high levels of CAU here detected in the fish
brain suggest that, in addition to the metabolic alterations discussed above, behavioural responses
to the C. cylindracea-based diet could also have substantial impact over time on D. sargus population
structure and ecology.
From a different perspective, however, the present study provides novel information that could
help to turn the threat into an opportunity of combining sustainable development of the sea-based
economy and conservation strategies. A first possible application of the results presented in this
study could be the use of selected species of Caulerpa as functional foods. Feather-like species, such as
C. taxifolia and C. sertularioides, contain high concentrations of the toxic sesquiterpene caulerpenyne
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(CYN) [4–6]. Conversely, other Caulerpa algae, collectively called “green caviar” or “sea grapes,”
are widely exploited for human consumption in Indo-Pacific and Caribbean regions [38]: among
these, C. racemosa and C. lentillifera, as well as C. cylindracea, are particularly suitable because of their
low content in CYN [39,40], while they are rich in CAU [4,5,41]. Different opinions still persist on
CAU toxicity [42] but the lack of acute toxicity assessed in the current study by in vitro toxicological
tests at the relatively high maximum dose (10 µM) (Figure 6i), supports the hypothesis that the
toxic symptoms observed in humans after ingestion of Caulerpa algae are most probably due to
other algal components [43], including the toxic metabolite CYN. Sea grapes are mainly considered
conventional foods [40] or generic dietary supplements for their fiber, anti-oxidant and other nutrients
content [44]; their use as functional foods has been also considered based on possible antinociceptive
and anti-inflammatory effects of CAU and sulphated polysaccharides [28,44,45]. The present study,
by identifying CAU as a non-toxic PPAR agonist, opens up new perspectives for the exploitation of the
invasive sea grape C. cylindracea, as a source of a novel functional ingredient potentially useful in the
prevention of lifestyle-related diseases [46].
PPAR ligands are being considered also for their therapeutic potential in the control of
metabolic disorders (i.e., hyperlipidaemia), atherosclerosis and for the treatment of the Alzheimer’s
disease [47,48]. Given the situation of high uncertainty in the management of invasive pests in the
Mediterranean Basin, the valorisation for pharmaceutical and nutraceutical purposes of undesired
algal biomasses could propel their removal, thus helping to reduce the pressure of such invasive
species [4].
Overall, our work demonstrates the validity of an interdisciplinary approach to delve deeper
into molecular mechanisms of action through which specific natural substances from marine pests
potentially exert cascade effects in the entire marine ecosystem, from molecular to progressively higher
levels of biological complexity, up to fisheries-based economy. In addition, the identification of CAU
as a PPAR agonist provides a suitable framework for mission-oriented projects that could make the
control (i.e., the harvesting) of C. cylindracea a profitable and “virtuous” activity.
4. Materials and Methods
4.1. Computational Studies
Computational methods have been utilized to compare the molecular structure of CAU with
typical PPAR agonists and to predict and characterize its possible direct interaction with PPARα and
PPARγ. Starting ligand geometry for ligand-based analysis and molecular docking was built with
Ghemical 2.99.2 [49], followed by energy minimization (EM) at the molecular mechanics level first,
using Tripos 5.2 force field parametrization [50] and then at the AM1 semi-empirical level. CAU was
fully optimized using GAMESS [51] at the Hartree-Fock level with STO-3G basis set to derive the partial
atomic charges using the RESP procedure of restrained fit to the HF/6-31G*/STO-3G electrostatic
potential [52]. Docking studies were performed with AutoDock 4.2 [51]. Two crystallographic
structures of both PPARα (PDB entry 2P54 and 1K7L) and PPARγ (PDB entry 2F4B and 4JAZ),
complexed with different full agonists and the ligand were processed with AutoDock Tools (ADT)
package version 1.5.6rc1 [53] to merge non polar hydrogens, calculate Gasteiger charges and select
rotatable side-chain bonds. Grids for docking evaluation with a spacing of 0.375 Å and 70 × 60 × 70
points, centred in the ligand binding pocket, were generated using the program AutoGrid 4.2 included
in Autodock 4.2 distribution. PPARα M330/M335, M330/I354/M355, M355/F318/Y314 and PPARγ
M348/M364, M348/F363/M364, Y327/H449/M364 sidechains were selected as rotatable in different
docking runs. One hundred molecular docking runs were performed with this setup: Lamarckian
Genetic Algorithm (LGA), 100 individuals in a population with a maximum of 15 million energy
evaluations and a maximum of 37,000 generations, followed by 300 iterations of Solis and Wets
local search. The non-redundant representative poses from the most populated clusters within
1 Kcal/mol from the complex endowed with the most favourable binding energy were selected for the
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subsequent MD simulations of ligand-PPARα/γ complex. The complexes were completed by addition
of all hydrogen atoms and underwent EM and then MD simulations with Amber16 pmemd.cuda
module [54–56], using ff14SB version of AMBER force field [57] for the protein and gaff parameters [58]
for the ligand. To perform molecular dynamics (MD) simulation in solvent, the complexes were
confined in TIP3P water periodic truncated octahedron boxes exhibiting a minimum distance between
solute and box surfaces of 10 Å, using the tleap module of AmberTools16 program [57]. The systems
were then neutralized by addition of counterions (Na+) and underwent 1000 steps of EM with solute
atoms harmonically restrained to their starting positions using a force constant of 10 kcal mol−1 Å−1.
90 ps restrained MD (5 kcal mol−1 Å−1) at constant volume was run on each solvated complex,
gradually heating the system to 300 K, followed by 60 ps restrained MD (5 kcal mol−1 Å−1) at constant
temperature (300 K) and pressure (1 atm) to adjust system density. Production MD simulations
were carried out at constant temperature (300 K) and pressure (1 atm) for 50 ns, prolonged to 100 ns
if rearrangements were observed during the first 50 ns, with a time-step of 2 fs. Bonds involving
hydrogens were constrained using the SHAKE algorithm [59].
4.2. Extraction and Purification of CAU from C. Cylindracea
CAU purification involved the extraction of C. cylindracea with acetone followed by partition
between diethyl ether and water. The diethyl ether extract was subjected to silica gel and sephadex
LH-20 column chromatography to give pure CAU (orange prisms) identified by comparison of 1H-
and 13C-NMR recorded data in DMSO-d6 with the literature values [60,61]. NMR spectra (Figures
S1–S2) were recorded on a 400 MHz Bruker Avance III HD spectrometer equipped with a CryoProbe
Prodigy. Chemical shift values were referenced to the residual solvent peaks (δH 2.49 ppm and δC
39.5 ppm)
4.3. Luciferase Reporter Assays
Evidence for direct binding and activation of PPARs by CAU was provided by luciferase-based
techniques. COS-7 cells (monkey kidney fibroblast-like cells) for PPARα and PPARγ luciferase reporter
assays were grown in DMEM with L-Glutamine supplemented with 10% foetal bovine serum and
1% Pen/Strep under standard conditions. Cells were plated in a 24-well dishes at 70% confluence
and transfected using Lipofectamine LTX and PLUS Reagent (Life Technologies, CA, USA: cat. no.
15338-100) according to the manufacture’s instruction.
For the experiments on the CAU-mediated activation of PPARα and PPARγ, at day 1, for each
well, a combination of 25 ng of mouse PSG5- PPARα (Addgene, MA, USA: cat. no. 22751) or mouse
PPARγ1 (Addgene, MA, USA: cat. no. 8886), 300 ng of PPRE X3-TK-luc; (Addgene, MA, USA: cat. no.
1015), 100 ng of pSV-β-Galactosidase Control Vector (Promega, WI, USA: cat. no. E1081) and 75 ng
pcDNA3 (Invitrogen, CA, USA) empty vector to a total of 500 ng were transfected.
The next day, the growth media was replaced with fresh media containing CAU or positive
controls in DMSO (vehicle) and treated overnight. In particular, fenofibrate 10 µM (FFB, Sigma Aldrich,
MO, USA: cat. no. F6020) and rosiglitazone 0.01 µM (RGZ, Tocris Bioscience, MN, USA: cat. no. 5325,)
were used respectively as PPARα and PPARγ agonists to be compared with CAU 1-30 µM. At day 3
after 18 h of treatment the cells were harvested and processed for the Luciferase and β-Galactosidase
detection analysis. The Luciferase Gene Reporter activity was detected using the Luciferase kit (Sigma
Aldrich, MO, USA: cat. no. LUC1) whereas the β-Galactosidase Activity was detected with the
β-Galactosidase detection kit (Sigma Aldrich, MO, USA: cat. no. Gal-A). The β-Gal expression was
quantified with the Microplate Readers (Tecan, Switzerland) and used as an internal experimental
control to analyse the transfection efficiencies in each cell sample group. The levels of Firefly Luciferase
chemiluminescence intensity was detected on a ChemiDoc MP system station using the Imagelab
software (Bio-Rad, CA, USA) and normalized with respect to the β-Gal expression.
To rule out the possible direct activation of RXR by CAU, COS-7 cells were grown, plated
and transfected as described above. Briefly, at day1, for each well, a combination of 25 ng of
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CMX-Gal4-hRXRα (kindly provided by Steven Kliewer); 300 ng of TK-MH100x4-Luc containing the
UAS enhancer elements (kindly provided by Steven Kliewer); 100 ng of pSV-β-Galactosidase Control
Vector (Promega, WI, USA: cat. no. E1081) and 75 ng pcDNA3 (Invitrogen, CA, USA) empty vector
to a total of 500 ng were transfected. The next day, the growth media was replaced with fresh media
containing 9-cis retinoic acid 0.01 µM (9-cis-RA, Sigma Aldrich, MO, USA: cat. no. R4643) as a RXRα
agonist and treated overnight in comparison with CAU 10 µM. DMSO was used as vehicle. At day 3
after 18 h of treatment the cells were harvested and processed for the Luciferase and β-Galactosidase
detection analysis.
4.4. In Vivo Experiments on D. sargus
Animal handling and experimental procedures were approved by the University of Napoli
“Federico II” ethical committee on animal experiments (ethical permit protocol n. 2013/0096061
of 10/31/2013). The studies were conducted at the animal facility of the Department of Biology,
University of Napoli “Federico II,” Napoli (Italy). Juvenile D. sargus were caught using a narrow mesh
net. 10 fishes were distributed into two 100 L glass aquaria (five fish each) in a close circuit with a
100 L sump setup holding a mechanical and biological filter, a protein skimmer and a zeolite reactor.
One aquarium was used as control and one for testing CAU-treated food. The fish were kept at 12 h
light/12 h dark cycle at the temperature of 18 ◦C. Fish were fed once per day with 1 g of dry food per
tank. Control food was prepared by soaking 30 g of Tetra Discus food granules (Tetra) in 60 mL acetone
and then evaporating the organic solvent under reduced pressure, while treated food was made in
the same manner but after dissolving 33.0 mg of CAU in the acetone. The dose of administered CAU
was ten times higher than that measured in C. cylindracea, to assess short time accumulation in fish
tissues. After one month of treatment the fish were euthanatized with an overdose of MS222 (tricaine
methane sulfonate) (>150 mg/L), dissected and tissues (livers, brains and white muscles) frozen in
liquid nitrogen and stored at −80 ◦C before the analyses (quantification of CAU and quantitative PCR
of PPARα).
4.5. Ex Vivo Exposures on Precision-Cut Liver Slices (PCLS) of D. sargus
Adults of D. sargus (27± 2 cm; 500± 150 g) were obtained from an aquaculture farm, acclimatized
in 90 L tanks at 18 ◦C for at least 2 weeks and fed daily, with commercial food. Fish were anesthetized
on ice and sacrificed by decapitation. The livers were rapidly excised, placed in cold (4 ◦C) Hank’s
Balanced Salt Solution (HBSS: KCl 0.40 g/L, KH2PO4 0.06 g/L, NaCl 18 g/L, Na2HPO4 0.05 g/L,
D-glucose 1 g/L, pH 7.4, supplemented with 1% penicillin/streptomycin antibiotics mix) and washed
by a cold HBSS flow through the main vessels to remove the blood and preserve the tissue from warm
ischemia. For preparation of the slices, the liver was divided into pieces of approximately 5 × 5 mm
sectioning area, using a sterile blade. Each piece of tissue was embedded in an agarose gel cylinder
(2.5% low melting point agarose, cooled under 30 ◦C), to facilitate the slicing procedure. 250 µm slices
were cut using a Leica vibrating blade vibratome VT1200S (Leica, Wetzlar, Germany) with a razor blade
at the following settings: speed 0.2 mm/s; amplitude 1.0 mm; knife angle 18◦. The whole procedure
was carried on in cold HBSS. The slices were placed in 12-well culture plates (two slices per well),
with 1.5 mL L-15 Leibovitz’s medium, supplemented with 10% FBS, 1% pen/strep mix and NaCl to a
final concentration 18 g/L (L-15+). Slices were incubated on an orbital shaker at 18 ◦C under normal
atmosphere. A 30 min pre-incubation was performed to remove any residual dead cells due to slicing.
After the pre-incubation period, PCLS were exposed to CAU (purified as described in Section 2.2)
and FFB dissolved in DMSO and used at a final 10 µM concentration in L-15+ medium. A solvent
control plate with DMSO in L-15+ was also included. Exposed and control slices were cut from the
same liver and incubated in parallel. After 6 h, 12 h and 24 h exposure, the slices were pooled (4 slices),
frozen in liquid nitrogen and stored at −80 ◦C until subsequent RNA extraction and qPCR analyses.
The exposure experiment was replicated for three different individual fish (n = 3).
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4.6. In Vitro Experiments on HepG2 Cells
HepG2 cells were grown in DMEM with L-Glutamine supplemented with 10% foetal bovine
serum and 1% Pen/Strep under standard conditions. Cells were cultured in 6 well plate and treated
with CAU (3 µM and 10 µM) and FFB (10 µM) for 6, 24 and 48 h. After treatment the cells were washed
in PBX 1X and used for subsequent quantitative PCR analysis and Western Blot.
4.7. LC-MS Quantification of CAU in D. sargus Tissues
Samples of fish tissues (livers, brains and white muscles) obtained from in vivo experiments on
D. sargus, were lyophilized and exhaustively extracted with acetone followed by partition between ethyl
acetate and water. Levels of CAU accumulation in liver, brain and white muscle tissue of each specimen
were measured by ultraperformance liquid chromatography/mass spectrometry (UPLC-MS/MS) by
using an API 3200 Triple Quadrupole mass spectrometer (SCIEX, Framingham, MA, USA), following
previously described methodologies [12,17]. Before extraction, indoleacrylic acid methyl ester was
added as an internal standard. UPLC-MS/MS analyses of biological replicates are reported as mean
(±SE, n = 3) values in µg g−1 (Figure 5a).
4.8. Quantification of Transcript Levels by qPCR
For in vivo and ex vivo samples obtained from D. sargus exposure experiments, absolute
quantitative real-time PCR (qPCR) was performed to determine mRNA levels of specific target
genes: PPARα in livers of D. sargus treated with CAU in vivo; PPARα, ACADM (acyl CoA
dehydrogenase medium chain) and ACOX1 (acyl CoA oxidase 1) in D. sargus PCLS treated
with CAU and FFB ex vivo. Total RNA was purified with Trizol reagent (Invitrogen, CA, USA),
according to the manufacturer’s protocol and quantified using Nano-Drop ND-1000 UV-Visible
Spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). RNA quality was verified
on an agarose-formaldehyde gel. Total cDNA was reverse transcribed from 1 µg of total RNA for
each sample using combined oligo(dT) and random hexamer primers (iScript cDNA Synthesis
Kit, Bio-Rad). qPCR was performed using SYBR green method in StepOnePlus®Real-Time
PCR System (Applied Biosystems) with specific primer pairs: PPARα (HG003581—96
bp amplicon): TGAGGGAGATCCACGGAGCCT (Fwd), TGAACGGCTGCTTGCTGGTCT
(Rev); ACOX1 (LT671670—110 bp amplicon): GCTGATGAAATATGCCAAGGTG
(Fwd), ACTCGCCAACAATCATGGA (Rev); ACADM (LT671671—122 bp amplicon):
GTGAAGATGGGCGATGAGTATG (Fwd), TTGCTGGTTGGACATTTAGGATC (Rev). Each 15 µL
DNA amplification reaction contained 7.5 µL of SYBR Select Master Mix (Life Technologies), 5 µL
of total cDNA (diluted 1:5) and 200 nM of each forward and reverse primers. The real-time PCR
program included an enzyme activation step at 95 ◦C (2 min) and 40 cycles each composed by 15 s at
95 ◦C, 15 s at the annealing temperature (PPARα: 62 ◦C; ACOX1: 59 ◦C; ACADM: 65 ◦C) and 1 min
at 72 ◦C. The specificity of target cDNA amplification was checked by including controls lacking
cDNA template and by a melting analysis (95 ◦C for 1 min, 65 ◦C for 10 s and fluorescence detection at
increasing temperature between 65 and 95 ◦C). For each target gene, serial dilutions of known amounts
of plasmid containing the amplicon of interest were used as standards. Samples and standards were
run in duplicate in the same run. Cycle threshold (Ct) values of unknown samples were converted
into mRNA copy number interpolating the standard plot of Ct versus log copy number.
For in vitro samples of HepG2 cells exposed to CAU and FFB, the cells were immersed in
Trizol (Invitrogen, CA, USA) after 1 wash in PBX 1X. RNA was subsequently collected using
Pure link RNA Mini Kit (Invitrogen, CA, USA). Extracted RNA was then treated with DNase-I
(1 U/mL; Sigma-Aldrich, MO, USA) following the manufacturer’s instructions. RNA integrity
was estimated on the 1% agarose gel. 1 µg of total RNA was reverse transcribed ISCRIPT RT
SUPERMIX (Biorad, CA, USA: cat. no. 1708841) according to the manufacturers’ instructions.
Quantitative PCR was carried out in a real-time PCR system CFX384 (Bio-Rad) using the Sso
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Advanced SYBR Green supermix (Bio-Rad, CA, USA: cat. no. 170-8842). Expression levels
were standardized to RPL27 as reference gene and all the data were analysed using 2−∆∆Ct
Livak Method by using the following specific forward and reverse primers: Human RPL27 (123
bp amplicon): ATCGCCAAGAGATCAAAGATAA (Fwd), TCTGAAGACATCCTTATTGACG
(Rev); Human ACADM (114 bp amplicon): AAGCTACTTGTAGAGCACCAAGC
(Fwd), ACGACCAGAATCAACCTCCC (Rev); Human CPT1A (136 bp amplicon):
CTACACGGCCGATGTTACGA (Fwd), TGACGTACTCCCAAAGGTGG (Rev); Human ACOX1
(135 bp amplicon): AAGTATGCCCAGGTGAAGCC (Fwd), AATGGTGCACGCCTTAGACA
(Rev); Human PPARα (137 bp amplicon): GCGAACGATTCGACTCAAGC (Fwd),
AACGAATCGCGTTGTGTGAC (Rev).
4.9. Western Methods
HepG2 cells treated with different compounds for 48 h were further analysed through Western
Blot for protein expression. Cells were washed two times in cold PBS and lysed with lysis solution
(150 mM NaCl, 1 mM EDTA, pH 7.4, 10 mM Tris-HCl, pH 8, 1% SDS and protease inhibitors). Lysates
were then placed on an orbital shaker and incubated at 4 ◦C for 30 min. Subsequently, lysates were
centrifuged for 15 min at 13,000× g at 4 ◦C and the supernatants transferred into clear tubes and
quantified by DC Protein Assay (Bio-Rad). Subsequently, the samples (80 µg of total protein) were
incubated for 10 min in bolt buffer plus sample reducing agents (Thermo Fisher Scientific, MA, USA)
and loaded on bis-tris plus precast polyacrylamide gel (4–12%, Thermo Fisher Scientific, MA, USA:
cat. no. NW04120BOX) and then transferred to a PVDF membrane. Filters were incubated overnight
at 4 ◦C with the rabbit monoclonal anti-CPT1A, 1-1000, (Cell Signalling Technology, MA, USA: cat.
no. 12252) and mouse monoclonal anti-tubulin, 1-5000, ( Sigma–Aldrich, MO, USA: cat. no. T8203)
that was used to check for equal protein loading. Reactive bands were detected by chemiluminescence
(ECL or ECL-plus; Perkin-Elmer). Images densitometry were analysed by means of Image J software.
4.10. MTT Assays
For toxicological evaluations, HepG2 cells were grown in DMEM with L-Glutamine and 1%
Pen/Strep under standard conditions without supplemented with 10% foetal bovine serum in 48-well
dishes. After adhesion, cells were serum-deprived and treated with the desired concentrations of
compounds for 18 h and 36 h (the absence of serum was maintained during the treatments). The ability
of cells to reduce MTT provided an indication of the mitochondrial integrity and activity and has been
interpreted as a measure of cell viability. Absorbance at 620 nm was read on a GENius- Pro 96/384
Multifunction Microplate Reader (GENios-Pro, Tecan, Milan, Italy). Compounds were dissolved in
DMSO. Optical density values from vehicle treated cells were defined as 100% of MTT-reducing activity
and the effects were measured as a % of the inhibition of the measures obtained with vehicle alone.
4.11. Statistical Analysis
Data sets were compared by use of unpaired t-tests or, if necessary, with one-way ANOVA,
followed by the Dunette’s multiple comparison test using GraphPad Prism 7 software. Statistically
significant differences were accepted when the p value was at least <0.05. Data were expressed as
mean ± SEM of the given number of experiments (n).
5. Conclusions
This work represents a paradigmatic model in the study of biological invasions at the level
of molecular interactions. In particular, it delves deeper into molecular mechanisms underpinning
metabolic and behavioural disorders occurring in D. sargus, a native fish playing key ecological
roles and representing a popular food item in the Mediterranean, feeding on the invasive alga
C. cylindracea. Our results disclose unprecedented molecular interactions likely exerting cascade
effects between different levels of complexity, from cell receptor modulation, through physiological
Mar. Drugs 2018, 16, 431 13 of 16
effects, to ecosystems, up to the sea-based economy. They also pave the way for the valorisation of
invasive biomasses through the development of functional foods for human nutrition and/or drugs
for treating chronic diseases (e.g. diabetes, obesity, atherosclerosis), prevalent in developed societies.
Supplementary Materials: The following are available online at http://www.mdpi.com/1660-3397/16/11/431/
s1, Video S1: D. sargus eating C. cylindracea, Figure S1: 1H NMR spectrum of CAU, Figure S2: 13C-NMR spectrum
of CAU
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